ORGO — Organogenesis Holdings Income Statement
0.000.00%
Last trade - 00:00
- $344.42m
- $309.78m
- $433.14m
- 81
- 50
- 49
- 62
R2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 261 | 338 | 468 | 451 | 433 |
Cost of Revenue | |||||
Gross Profit | 185 | 251 | 354 | 346 | 327 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 293 | 309 | 397 | 429 | 421 |
Operating Profit | -31.7 | 28.9 | 71 | 22.3 | 12.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -38.6 | 17.8 | 63.8 | 20.3 | 10.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -38.7 | 17.2 | 94.9 | 15.5 | 4.95 |
Net Income Before Extraordinary Items | |||||
Net Income | -38.7 | 17.2 | 94.9 | 15.5 | 4.95 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -39.3 | 17.2 | 94.9 | 15.5 | 4.95 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.41 | 0.141 | 0.742 | 0.13 | 0.051 |